First human tests: does kidney health change how a new drug works?
NCT ID NCT07154901
Summary
This early-stage study aims to understand how a new drug, opemalirsen, is processed by the body in people with different levels of kidney function compared to people with normal kidney function. About 50 adults, some with kidney impairment and some without, will receive a single dose of the drug. Researchers will measure drug levels in the blood and urine and check for side effects to see if the dose needs adjustment for people with kidney problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGMiami, Florida, 33172, United States
-
Research Site
RECRUITINGOrlando, Florida, 32808, United States
Conditions
Explore the condition pages connected to this study.